Previous studies have shown that the downregulation of PDIA3 is related to the poor prognosis of early cervical cancer, and PDIA3 expression shows significant differences in different histological types of cervical cancer, which has a direct impact on drug therapy and clinical application and can be regarded as a potential and specific prognosis and therapeutic target of cervical cancer [18–20]. The gene discussed is PDIA3; the disease is cervical carcinoma.